Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company

C4 Therapeutics Outlines 2024 Focus Amid 30% Workforce Reduction, Prioritizes Key Oncology Trials

Fineline Cube Jan 11, 2024

C4 Therapeutics (NASDAQ: CCCC), a leader in protein degradation, announced this week its strategic focus...

Company

Sanofi CEO Paul Hudson Rules Out GLP-1 Competition, Eyes Next-Gen Weight-Management Therapies

Fineline Cube Jan 11, 2024

Paul Hudson, CEO of Sanofi (NASDAQ: SNY), stated this week that the France-based pharmaceutical company...

Policy / Regulatory

Corruption Investigations Target Former HSA Officials in Guizhou and Hainan Amid Nationwide Crackdown

Fineline Cube Jan 11, 2024

Corruption investigations have been launched against former senior officials of the Healthcare Security Administration (HSA)...

Company Deals

Henlius Biotech Secures Exclusive Rights to Sermonix’s Lasofoxifene for Breast Cancer Treatment in China

Fineline Cube Jan 11, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a partnership and licensing agreement with...

Company Drug

GenFleet’s SLS009 Receives Fast-Track and Orphan Drug Designations from U.S. FDA for Lymphoma and Leukemia

Fineline Cube Jan 11, 2024

Shanghai-based biotech GenFleet Therapeutics announced that its CDK9 inhibitor, SLS009 (GFH009), has received fast-track and...

Company Deals

GSK’s Acquisition of Aiolos Bio Bolsters Respiratory Medicine Portfolio with AIO-001

Fineline Cube Jan 10, 2024

UK pharmaceutical giant GSK plc (LON: GSK) has announced a deal to acquire Aiolos Bio,...

Company

WuXi AppTec Expands Peptide Manufacturing Capacity with Two New Plants in China

Fineline Cube Jan 10, 2024

WuXi AppTec (HKG: 2359, SHA: 603259), a leading China-based Contract Research, Development, and Manufacturing Organization...

Company Medical Device

Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Bangladesh

Fineline Cube Jan 10, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical device company, has announced that...

Company Drug

Novartis’s Cosentyx Secures Additional Indication for Psoriatic Arthritis in China

Fineline Cube Jan 10, 2024

Swiss pharmaceutical giant Novartis (SWX: NOVN) has announced that its drug Cosentyx (secukinumab), which targets...

Company Drug

Pfizer and Genmab’s Tivdak Earns Priority Review from FDA for Full Registration

Fineline Cube Jan 10, 2024

The US Food and Drug Administration (FDA) has accepted for priority review a filing from...

Company

International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation

Fineline Cube Jan 10, 2024

The International Society for Cell & Gene Therapy (ISCT) has published a statement addressing the...

Company Hospital

Meizhong Jiahe Medical Debuts on Hong Kong Stock Exchange Below IPO Price

Fineline Cube Jan 10, 2024

China-based Meizhong Jiahe Medical Science & Technology Development Co., Ltd has completed its initial public...

Company Drug Medical Device

AbbVie Launches Continuous Infusion Therapy for Advanced Parkinson’s Disease in EU

Fineline Cube Jan 10, 2024

AbbVie (NYSE: ABBV) has announced the launch of its dopamine replacement therapy, Produodopa (foslevodopa +...

Company Drug

OBI Pharma Gets US FDA Green Light for TROP2 Targeting ADC Cancer Therapy Clinical Study

Fineline Cube Jan 10, 2024

OBI Pharma (4174.TWO), partner to Biosion Inc., has announced that it has received approval from...

Company Deals

Bio-Link Partners with Verdot to Distribute Innovative Bioprocessing Products in China

Fineline Cube Jan 10, 2024

Bio-Link Biological Applied Technologies (Shanghai) Co., Ltd., a leading provider of life sciences industry solutions...

Company Deals

Synvida Raises Nearly RMB 200 Million in Series A Funding to Advance Clinical Studies

Fineline Cube Jan 10, 2024

Synvida, a biotech company incubated by Shanghai Pharma (HKG: 2607, SHA: 601607) and Shanghai Healthcare...

Company Deals Medical Device

Sinocare Partners with Illumina to Localize iScan Chip Scanners for Precision Health Applications

Fineline Cube Jan 10, 2024

Sinocare Inc. (SHE: 300298), a China-based company, has entered into a partnership agreement with U.S....

Company Deals

Johnson & Johnson to Acquire Ambrx Biopharma in a Deal Valued at USD 2 Billion

Fineline Cube Jan 9, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has announced its intention to...

Company Drug

MSD’s Gardasil 9 Receives NMPA Approval for Two-Dose Schedule in Younger Females

Fineline Cube Jan 9, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a prominent pharmaceutical company in the U.S., has...

Company Drug

Astellas’ Zolbetuximab Faces FDA Rejection Due to Manufacturing Facility Deficiencies

Fineline Cube Jan 9, 2024

The US Food and Drug Administration (FDA) has issued a rejection for a filing submitted...

Posts pagination

1 … 363 364 365 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.